OncoGenex Technologies   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Bothell WA United States (1991)
Status: Acquired by Achieve Life Sciences (2017)

Organization Overview

First Clinical Trial
2002
NCT00034151
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Colorectal Neoplasms (Phase 1)

Lung Neoplasms (Phase 3)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Pelvic Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 3)

Ureteral Neoplasms (Phase 2)

Urethral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Urologic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 15